Cancer with moderate to severe Depression
Conditions
Interventions
Case series:Fluvoxamine maleate tablet
Sponsors
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years; 2. Patients diagnosed as malignant tumor by cytology and pathology; 3. Patients with life expectancy more than 6 months; 4. Patients with he initial screening of the hospital anxiety and depression scale (HAD) positive; 5. Patients diagnosed as a depressive state according to the guidelines for the prevention and treatment of depressive disorders 2007, and diagnosed by depression scale (HAMD) with moderate and severe depression (score > 17 Points); 6. Patients voluntarily participated and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients without oral expression ability; 2. Patients with cognitive impairment; 3. Patients with poor pain control; 4. Patients who knew the tumor condition for less than 1 month; 5. Patients with tumor origin or metastasis to the central nervous system; 6. Pregnant or lactating patients; 7. Patients with istory of allergy to fluvoxamine maleate or its excipients; 8. Patients with severe suicidal tendencies; 9. Patients with severe comorbidity and unstable control in the next 2 months; 10. Patients with a history of epilepsy; 11. Participants in other clinical drug trials within 30 days; 12. Patients who had taken other antidepressants within 2 weeks before inclusion; 13. Unsupervised or unable to take prescribed medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Scale;Mos-ss sleep scale; | — |
Countries
China
Contacts
Public ContactShiying Yu
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed